COMMUNIQUÉS West-GlobeNewswire

Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition
03/12/2018
BERKELEY, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301 supporting its potential use [...]
Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors
03/12/2018
ROCKVILLE, Md., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that [...]
Study of Feraheme demonstrates Improvements in Fatigue and Quality Of Life in Iron Deficiency Anemia Patients
03/12/2018
Key Findings of a 6-Month Extension Study Presented at the American Society of Hematology Annual Meeting WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that [...]
Tabula Rasa HealthCare to Acquire DoseMe, a Precision Dosing Software Company
03/12/2018
Acquisition projected to expand reach of TRHC’s medication safety technologies in the hospital healthcare system market and internationally MOORESTOWN, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc [...]
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
03/12/2018
LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, [...]
LogicBio Reports Third Quarter 2018 Financial Results
03/12/2018
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in [...]
Tetra Natural Health Will Deliver 20 containers of Hemp Energy Drink to Meet Consumer Demand
03/12/2018
ORLEANS, Ontario, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its [...]
Tetra Santé Naturelle livrera 20 conteneurs de Hemp Energy Drink pour répondre à la demande
03/12/2018
ORLEANS, Ontario, 03 déc. 2018 (GLOBE NEWSWIRE) -- Tetra Santé Naturelle, une filiale de Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), annonce la livraison de vingt (20) conteneurs, soit plus de 1,7 millions de [...]
Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data
03/12/2018
JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance [...]
Nephros to Present at the 11th Annual LD Micro Main Event
03/12/2018
Presentation Scheduled for 9:30 AM PT on Tuesday, December 4th SOUTH ORANGE, NJ, Dec. 03, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a commercial stage medical device company [...]
Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
03/12/2018
Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of 34% ORR of 54% and CR/Partial Response (PR) [...]
Theratechnologies Appoints New Chief Commercial Officer
03/12/2018
MONTREAL, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce the appointment of Mr. Jovan Antunovic as Senior Vice President and Chief Commercial Officer. “ [...]
Theratechnologies nomme un nouveau chef de l’exploitation commerciale
03/12/2018
MONTRÉAL, 03 déc. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer la nomination de M. Jovan Antunovic à titre de vice-président principal et chef de l’exploitation [...]
Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting
03/12/2018
XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, [...]
Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
03/12/2018
Expands medical device production capabilities SAN DIEGO and TOKYO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced that the Company has received approval [...]
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
03/12/2018
Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects Observed corresponding trends of improvement on multiple secondary endpoints, including [...]
Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting
03/12/2018
HOUSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]
OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
03/12/2018
CG-806 Pan-FLT3/Pan-BTK Inhibitor Exhibits Favorable Safety Profile and Unexpected Potency on Primary Cells from B-cell Cancer Patients and AML Patients PORTLAND, Ore. and SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- [...]
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
03/12/2018
Data elucidate unique ability of CG-806 to overcome resistance to other FLT3 inhibitors in AML cells SAN DIEGO and TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today [...]

Pages